[
  {
    "ts": "2025-07-17T11:00:00+00:00",
    "headline": "Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States",
    "summary": "NASHVILLE, July 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter \"Samsung Bioepis\") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referenc",
    "url": "https://finance.yahoo.com/news/harrow-enters-commercialization-agreement-samsung-110000795.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "365d559d-1271-317b-bdd7-717f63d9a4a4",
      "content": {
        "id": "365d559d-1271-317b-bdd7-717f63d9a4a4",
        "contentType": "STORY",
        "title": "Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States",
        "description": "",
        "summary": "NASHVILLE, July 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter \"Samsung Bioepis\") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referenc",
        "pubDate": "2025-07-17T11:00:00Z",
        "displayTime": "2025-07-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/e3551beaa1af20946e091db7262956c7",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D3BXpbhs.dUXE9xwHJjpog--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e3551beaa1af20946e091db7262956c7.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G3drSEFPSHa20q5eQNOztA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e3551beaa1af20946e091db7262956c7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/harrow-enters-commercialization-agreement-samsung-110000795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/harrow-enters-commercialization-agreement-samsung-110000795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HROW"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-17T11:00:00+00:00",
    "headline": "Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States",
    "summary": "INCHEON, Korea, July 17, 2025--Samsung Bioepis Co., Ltd. (\"Samsung Bioepis\") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis’ ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon comple",
    "url": "https://finance.yahoo.com/news/samsung-bioepis-enters-partnership-harrow-110000401.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "4ea4844b-7819-3863-beb0-a80916738daf",
      "content": {
        "id": "4ea4844b-7819-3863-beb0-a80916738daf",
        "contentType": "STORY",
        "title": "Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States",
        "description": "",
        "summary": "INCHEON, Korea, July 17, 2025--Samsung Bioepis Co., Ltd. (\"Samsung Bioepis\") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis’ ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon comple",
        "pubDate": "2025-07-17T11:00:00Z",
        "displayTime": "2025-07-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/56fa58f5033157910267e56421ae4975",
          "originalWidth": 1270,
          "originalHeight": 458,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/74MadPD5QLi_u9BYW3nWfA--~B/aD00NTg7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/56fa58f5033157910267e56421ae4975.cf.webp",
              "width": 1270,
              "height": 458,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5N.w3h470nHwWgUnXVQTBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/56fa58f5033157910267e56421ae4975.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-enters-partnership-harrow-110000401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-enters-partnership-harrow-110000401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]